More News! Trump targets Pharma, €1B Deal for Ipsen, & a Hep B update

Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.

LesPalenik

  • Allergan has kicked off the new year with acquisitions in Parkinson’s and GI diseases
  • Newron has taken its business to Australia and New Zealand through a new partnership
  • Kymab collected €8.5M from the Bill & Melinda Gates Foundation to accelerate its infectious disease program
  • Ipsen is shelling out up to €1B for Merrimack’s pancreatic cancer treatment, Onivyde

Vladimir Wrangel

  • Gilead’s Hepatitis B treatment, Vemlidy (Tenofovir Alafenamide), is coming to Europe, the first of its kind in almost a decade
  • Antiviral research from Haplogen and Evotec has been published in Nature, spotlighting a new target

Lisa Hagan

  • Though ‘promise’ loses its meaning in the context of the American President-Elect, The Donald is threatening to slash drug prices.

Shar Pei or Towel?

CdPkrLiUEAASvu9


Images from Sharp, Les Palenik, Vladimir Wrangel and Lisa Hagan / shutterstock.com

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and it's freely accessible content.